Global Bupropion Hydrochloride Extended-Release Tablets Market Growth 2025-2031

The global Bupropion Hydrochloride Extended-Release Tablets market size is predicted to grow from US$ 4663 million in 2025 to US$ 6059 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.

Bupropion Hydrochloride Extended-Release Tablets (often abbreviated as Bupropion XR) are a type of antidepressant used to treat several conditions, including major depressive disorder (MDD), seasonal affective disorder (SAD), and smoking cessation (as part of a smoking cessation program). It is also sometimes prescribed for attention-deficit hyperactivity disorder (ADHD) and anxiety disorders. Bupropion is part of a class of drugs known as norepinephrine-dopamine reuptake inhibitors (NDRIs).

United States market for Bupropion Hydrochloride Extended-Release Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Bupropion Hydrochloride Extended-Release Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Bupropion Hydrochloride Extended-Release Tablets is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Bupropion Hydrochloride Extended-Release Tablets players cover GlaxoSmithKline, Valeant International Barbados SRL, Teva Pharmaceuticals, ProPhase, Dr. Reddy's, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Bupropion Hydrochloride Extended-Release Tablets Industry Forecast” looks at past sales and reviews total world Bupropion Hydrochloride Extended-Release Tablets sales in 2024, providing a comprehensive analysis by region and market sector of projected Bupropion Hydrochloride Extended-Release Tablets sales for 2025 through 2031. With Bupropion Hydrochloride Extended-Release Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bupropion Hydrochloride Extended-Release Tablets industry.

This Insight Report provides a comprehensive analysis of the global Bupropion Hydrochloride Extended-Release Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bupropion Hydrochloride Extended-Release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bupropion Hydrochloride Extended-Release Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bupropion Hydrochloride Extended-Release Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bupropion Hydrochloride Extended-Release Tablets.

This report presents a comprehensive overview, market shares, and growth opportunities of Bupropion Hydrochloride Extended-Release Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
150mg
300mg

Segmentation by Application:
Hospital
Clinic
Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Valeant International Barbados SRL
Teva Pharmaceuticals
ProPhase
Dr. Reddy's
Yichang Humanwell Pharmaceutical
Disha
Sinotherapeutics
Venturepharm Pharmacetical
Shenyang Funing Pharmaceutical
Annora Pharma
Epic Pharma
Granules India
Impax Laboratories

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bupropion Hydrochloride Extended-Release Tablets market?

What factors are driving Bupropion Hydrochloride Extended-Release Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bupropion Hydrochloride Extended-Release Tablets market opportunities vary by end market size?

How does Bupropion Hydrochloride Extended-Release Tablets break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.